CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +8,674 | $11.40 | $99K | 1,144,843 |
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Sale | −36,319 | $11.86 | $431K | 1,108,524 |
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion | +4,000 | 4,000 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Sale | −4,000 | $11.56 | $46K | 0 |
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion | +20,000 | 20,000 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Sale | −20,000 | $11.55 | $231K | 0 |
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion | +1,000 | 1,000 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Sale | −1,000 | $11.56 | $12K | 0 |
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 312,500 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −8,674 | 399,002 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,461,496 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −4,000 | 511,000 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −20,000 | 388,000 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −1,000 | 117,875 | ||
| 2024-03-05 | Borgeson Blake Director | Sale 10b5-1 | −20,054 | $12.06 | $242K | 7,272,809 |
| 2024-02-22 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +8,000 | $1.06 | $8K | 647,982 |
| 2024-02-22 | Marriott Tina President and COO | Sale 10b5-1 | −8,000 | $14.90 | $119K | 639,982 |
| 2024-02-22 | Marriott Tina President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −8,000 | 496,000 | ||
| 2024-02-20 | Borgeson Blake Director | Sale 10b5-1 | −19,745 | $12.31 | $243K | 7,293,172 |
| 2024-02-20 | Borgeson Blake Director | Sale 10b5-1 | −309 | $13.04 | $4K | 7,292,863 |
Page 23 of 41 · 805 trades